Welcome to the 9th Neurodegenerative Drug Development Summit

As we await the FDA’s results to decide on the outcome of the aducanumab trial, this year is clearly a critical year for all those working on neurodegenerative R&D.

Back with a bang, in an all new digital format, the 9th Neurodegenerative Drug Development Summit is the industry’s definitive and unrivalled forum focused on revealing hot and promising pockets of innovation in drug discovery for neurodegenerative diseases and combating translational challenges by shining a light on pioneering companies leading the way to meet this dire medical need.

Building on the success of last year’s meeting, this year’s program showcases new biotechs trailblazing this space and will put the spotlight on the latest scientific advances in terms of diverse targets, novel modalities and innovative trial design.

Across 3 action-packed, case-study driven days and 2 parallel tracks of learning, we present the opportunity to join us online in 2021 to overcome technical and operational challenges preventing you and your team from translating promising preclinical research into evidenced clinical benefit.

Whether you are working in a team dedicated to Parkinson’s, Alzheimer’s, ALS, Frontotemporal Dementia or a rare neurodegenerative disorder, join this intimate, industry-led forum to not only to learn from those spearheading this space, but to network and build meaningful partnerships with over 180 neurodegenerative drug development experts. After all, collaboration in this industry is pivotal.

32 World-Class Speakers, Including:

Andrew Lim

Chief Executive Officer

Circumvent Pharmaceuticals

Dimitry Ofengeim

Precision Neurology and Neuroinflammation Head

Sanofi

Elena H Martínez-Lapiscina

Rare Neurological Disorders Lead - Clinical Neurologist

European Medicines Agency

Jeff Dage

Senior Research Advisor

Eli Lilly & Company

Henrik Zetterberg

Professor

University of Gothenburg

Jonathan Behr

Partner

Dementia Discovery Fund

Jonathan Levenson

Vice President of Translational Biology

Tiaki Therapeutics

Judith Kelleher-Andersson

President and CEO

Neuronascent

Mark Treherne

Chairman

Gen2 Neuroscience

Martin Tolar

Founder, President & CEO

Alzheon

Charlotte Teunissen

Professor Neurochemistry

VUmc

Daniel Lorrain

CSO

Pipeline Therapeutics

Krystof Bankiewicz

President & Chief Executive Officer, CEO

Brain Neurotherapy Bio, Columbus Children’s Foundation

Sanjay Kakkar

President & CEO

Tranquis Therapeutics

Vanessa Almendro

Head of Strategy & Operations

Eisai Center for Genetics Guided Dementia Discovery (G2D2)

Neurodegenerative Drug Development Summit is Proud to Partner With:

Bach Pharma

"The quality of the attendees and the speakers was outstanding. The speakers were exceptional, I was blown away. I'm still trying to recover" - Mark Henry, Chief Executive Officer & Chief Financial Officer, Bach Pharma

"High level meeting with leading neuroscientists attending across the biotech industry" - Johan Luthman, Executive Vice President & Head of Research & Development, H. Lundbeck
"The summit provided an excellent insight into the current state of research and provided a great forum for discussion. Made a lot of excellent contacts"- Steven Arnott, CEO, Perron Institute
"Good crop of speakers and attentive audience; the timing was just right; overall a very positive attitude... Informative talks, stimulating panel discussions, dedicated workshops, and challenging questions from an interactive and engaged audience made the 2020 NDD Summit a great vintage" - Christian Schubert, Director & Global Head of External BioInnovation, Research & Development, Servier
t
"NDD provided a great opportunity for discussion, feedback, and networking alongside an all star speaker line up" - Samantha Hutten, Senior Associate Director - Research Partnerships & Research Programs, The Michael J. Fox Foundation for Parkinson's Research
t

Other Events in the World CNS Series: